Lilly Endowment, the 10%-plus owner of Eli Lilly, has reported $111B+ in career Form 4 sell transactions. The December 2025 filing continues decades of systematic diversification.
United Therapeutics CEO Martine Rothblatt exercised options and sold UTHR shares worth ~$1.5M across December 17-19, 2025 at prices around $505-$511 per share.
Balu Balakrishnan sold Power Integrations stock across late January and early February 2026 as the company reported Q4 2025 results and announced a restructuring plan.
Richard Fairbank sold about $46.2M of Capital One stock across late October and early November 2025 as Capital One moved from merger approval to Discover integration.
John Hess sold about $142.7M of Chevron stock across November 20-21, 2025 after the Chevron-Hess deal closed, while his latest Hess 13G still showed 8.58% beneficial ownership.
Jensen Huang sold about $6.6M of Nvidia stock across October 28-29, 2025, but the later quarter still confirmed AI demand was running hot and he still held 69.7M shares after the latest trade.
SCHELLER RICHARD H disclosed roughly $464K of recent MAZE selling across a September 2025 window, making the pattern more useful as a cadence signal than a single-trade headline.
SARVADI PAUL J disclosed roughly $564K of recent NSP selling across a September 2025 window, making the pattern more useful as a cadence signal than a single-trade headline.
Louis Berkman Investment CO disclosed roughly $248K of recent AP buying during November 2025, putting fresh capital behind the position in the open market.
Lake Katrina disclosed roughly $2.3M of recent SFIX selling across a September 2025 to December 2025 window, making the pattern more useful as a cadence signal than a single-trade headline.
KOUNINIS EFSTATHIOS A sold roughly $755,764 of PEGA stock during a visible September-October 2025 liquidity window, making the pattern more useful as a cadence signal than a one-day headline.
LANSING WILLIAM J sold roughly $4.2M of FICO stock during a visible November 2025 liquidity window, making the pattern more useful as a cadence signal than a one-day headline.
Scott Farquhar and Mike Cannon-Brookes sold roughly $14.9M of Atlassian stock over the same late-January window, making the pattern look coordinated rather than incidental.
Martine Rothblatt sold roughly $8.4M of United Therapeutics stock across four December 2025 sessions, a pattern that looked more like disciplined exercise monetization than a blind exit.